We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

72 hedge funds and large institutions have $200M invested in ARS Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 27 increasing their positions, 18 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 18

3.35% more ownership

Funds ownership: 82.46% → 85.81% (+3.4%)

5% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 20

3% less funds holding

Funds holding: 74 → 72 (-2)

30% less capital invested

Capital invested by funds: $287M → $200M (-$87M)

Holders
72
Holders Change
-2
Holders Change %
-2.7%
% of All Funds
1.11%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
19
Increased
27
Reduced
18
Closed
20
Calls
$406K
Puts
–
Net Calls
+$406K
Net Calls Change
+$542K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$6.11M
2
Ensign Peak Advisors
Ensign Peak Advisors
Utah
+$3.33M
3
BlackRock
BlackRock
New York
+$2.86M
4
WA
Wasatch Advisors
Utah
+$2.78M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$2.44M

Top Sellers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
-$16.7M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.35M
3
Millennium Management
Millennium Management
New York
-$2.91M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$2.9M
5
Marshall Wace
Marshall Wace
United Kingdom
-$2.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
Janney Montgomery Scott
26
Janney Montgomery Scott
Pennsylvania
$564K +$562K +69,203 +446%
ECM
27
Endurant Capital Management
California
$561K +$685K +84,295 New
UBS Group
28
UBS Group
Switzerland
$525K +$529K +65,110 +474%
Acadian Asset Management
29
Acadian Asset Management
Massachusetts
$522K +$639K +78,634 New
Goldman Sachs
30
Goldman Sachs
New York
$521K +$194K +23,884 +44%
Nomura Holdings
31
Nomura Holdings
Japan
$461K +$558K +68,639 New
HF
32
HRT Financial
New York
$423K +$305K +37,554 +144%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$400K +$27.6K +3,393 +6%
N
34
Nuveen
North Carolina
$391K -$104K -12,743 -17%
OQS
35
Occudo Quantitative Strategies
Florida
$388K +$338K +41,539 +248%
PM
36
Prosight Management
Texas
$358K +$437K +53,815 New
CSS
37
Cubist Systematic Strategies
Connecticut
$297K -$101K -12,480 -22%
Ohio Public Employees Retirement System (OPERS)
38
Ohio Public Employees Retirement System (OPERS)
Ohio
$292K – – –
PPA
39
Parametric Portfolio Associates
Washington
$270K +$329K +40,518 New
JF
40
Jump Financial
Illinois
$252K +$43.1K +5,300 +16%
B
41
Bailard
California
$213K +$260K +32,000 New
TI
42
Trexquant Investment
Connecticut
$203K -$120K -14,718 -33%
Bank of America
43
Bank of America
North Carolina
$158K +$167K +20,490 +624%
HS
44
HighVista Strategies
Massachusetts
$149K – – –
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$141K +$9.99K +1,229 +6%
VF
46
Virtu Financial
New York
$135K +$165K +20,317 New
ECM
47
ExodusPoint Capital Management
New York
$128K +$156K +19,148 New
XT
48
XTX Topco
Cayman Islands
$125K +$153K +18,816 New
PP
49
PDT Partners
New York
$112K +$10.5K +1,289 +8%
PCM
50
Prelude Capital Management
New York
$111K +$136K +16,700 New
1
2
3 4

SPRY Hedge Fund Activity: Q4 2021 in Review

72 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q4 2021, worth a combined $200M — down 30% from $287M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of SPRY and 19 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 27 added.

The largest buyer was Morgan Stanley, adding an estimated $6.11M. The largest seller was Boxer Capital, exiting entirely with an estimated $16.7M sold.

  • 72 institutional investors held ARS Pharmaceuticals (SPRY) as of Q4 2021, down from 74 in Q3 2021.
  • Funds reported $200M of ARS Pharmaceuticals stock for Q4 2021, down 30% quarter-over-quarter.
  • 19 funds opened new ARS Pharmaceuticals positions in Q4 2021 and 20 closed out, a net change of -1 holder.
  • The largest ARS Pharmaceuticals buyer in Q4 2021 was Morgan Stanley, an estimated $6.11M added.
  • The largest ARS Pharmaceuticals seller in Q4 2021 was Boxer Capital, an estimated $16.7M sold.

Based on aggregated 13F filings for Q4 2021.